Published in PLoS One on May 19, 2014
SPR4-peptide alters bone metabolism of normal and HYP mice. Bone (2014) 0.80
A unified model for bone-renal mineral and energy metabolism. Curr Opin Pharmacol (2015) 0.80
Age dependent regulation of bone-mass and renal function by the MEPE ASARM-motif. Bone (2015) 0.80
Do ASARM peptides play a role in nephrogenic systemic fibrosis? Am J Physiol Renal Physiol (2015) 0.76
A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res (2001) 124.61
Uric acid and cardiovascular risk. N Engl J Med (2008) 12.20
Endocrine regulation of energy metabolism by the skeleton. Cell (2007) 10.41
Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell (2000) 7.87
Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet (2006) 7.53
Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell (2008) 5.93
Lrp5 functions in bone to regulate bone mass. Nat Med (2011) 5.33
Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell (2010) 5.08
A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet (1995) 4.61
DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet (2006) 4.49
A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell (2009) 3.28
PAT proteins, an ancient family of lipid droplet proteins that regulate cellular lipid stores. Biochim Biophys Acta (2009) 3.21
Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA (1991) 3.01
Dynamic rerouting of the carbohydrate flux is key to counteracting oxidative stress. J Biol (2007) 2.70
Secreted kinase phosphorylates extracellular proteins that regulate biomineralization. Science (2012) 2.55
Effect of insulin on uric acid excretion in humans. Am J Physiol (1995) 2.25
Inactivation of a novel FGF23 regulator, FAM20C, leads to hypophosphatemic rickets in mice. PLoS Genet (2012) 2.19
Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care (2001) 2.02
Peripheral leptin regulates bone formation. J Bone Miner Res (2013) 2.00
Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet (2010) 1.93
Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept (2000) 1.91
Decreased osteoclastogenesis in serotonin-deficient mice. Proc Natl Acad Sci U S A (2012) 1.84
Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis (2009) 1.83
Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J (2003) 1.80
MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone (2004) 1.79
Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice. J Bone Miner Res (2005) 1.70
Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J Biol Chem (2012) 1.67
Alterations of red-cell glycolytic intermediates and oxygen transport as a consequence of hypophosphatemia in patients receiving intravenous hyperalimentation. N Engl J Med (1971) 1.65
A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol Cell Endocrinol (2009) 1.64
The role of uric acid in the pathogenesis of human cardiovascular disease. Heart (2013) 1.59
Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone (2004) 1.57
Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology (1986) 1.57
Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol (2006) 1.56
The Raine syndrome protein FAM20C is a Golgi kinase that phosphorylates bio-mineralization proteins. PLoS One (2012) 1.54
Direct interaction of Plin2 with lipids on the surface of lipid droplets: a live cell FRET analysis. Am J Physiol Cell Physiol (2012) 1.54
MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM. J Bone Miner Res (2008) 1.52
The role of membrane glycoprotein plasma cell antigen 1/ectonucleotide pyrophosphatase phosphodiesterase 1 in the pathogenesis of insulin resistance and related abnormalities. Endocr Rev (2008) 1.52
Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology (2007) 1.51
Insulin stimulates glyceraldehyde-3-phosphate dehydrogenase gene expression through cis-acting DNA sequences. Proc Natl Acad Sci U S A (1988) 1.49
Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage. J Bone Miner Res (2010) 1.45
Pathophysiology of diabetic retinopathy. ISRN Ophthalmol (2013) 1.44
High plasma uric acid concentration: causes and consequences. Diabetol Metab Syndr (2012) 1.43
Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity. J Bone Miner Res (2014) 1.42
Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest (2008) 1.38
Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc Natl Acad Sci U S A (2014) 1.35
Perturbation of fuel homeostasis caused by overexpression of the glucose-6-phosphatase catalytic subunit in liver of normal rats. J Biol Chem (1998) 1.35
Oxygen tension is an important mediator of the transformation of osteoblasts to osteocytes. J Bone Miner Metab (2007) 1.34
European bone mineral density loci are also associated with BMD in East-Asian populations. PLoS One (2010) 1.29
Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator. Endocrinology (2009) 1.27
Exome sequencing reveals FAM20c mutations associated with fibroblast growth factor 23-related hypophosphatemia, dental anomalies, and ectopic calcification. J Bone Miner Res (2013) 1.26
The role of phosphatases in the initiation of skeletal mineralization. Calcif Tissue Int (2012) 1.26
Perilipin-2-null mice are protected against diet-induced obesity, adipose inflammation, and fatty liver disease. J Lipid Res (2013) 1.25
Increased hepatic levels of the insulin receptor inhibitor, PC-1/NPP1, induce insulin resistance and glucose intolerance. Diabetes (2005) 1.24
Insulin signaling regulating genes: effect on T2DM and cardiovascular risk. Nat Rev Endocrinol (2009) 1.19
Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res (2011) 1.19
Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J Endocrinol (2004) 1.19
Amelogenesis imperfecta and other biomineralization defects in Fam20a and Fam20c null mice. Vet Pathol (2012) 1.18
Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol (2007) 1.18
Serum uric acid is associated with bone health in older men: a cross-sectional population-based study. J Bone Miner Res (2011) 1.18
Altered bone development and an increase in FGF-23 expression in Enpp1(-/-) mice. PLoS One (2012) 1.18
Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin. Bone (2006) 1.18
Multistage genome-wide association meta-analyses identified two new loci for bone mineral density. Hum Mol Genet (2013) 1.17
Mutant Enpp1asj mice as a model for generalized arterial calcification of infancy. Dis Model Mech (2013) 1.17
Overexpression of the insulin receptor inhibitor PC-1/ENPP1 induces insulin resistance and hyperglycemia. Am J Physiol Endocrinol Metab (2005) 1.14
Human recombinant endopeptidase PHEX has a strict S1' specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein. Biochem J (2003) 1.12
Serum uric acid plays a protective role for bone loss in peri- and postmenopausal women: a longitudinal study. Bone (2012) 1.11
A study of bone mineral density and its determinants in type 1 diabetes mellitus. J Osteoporos (2013) 1.10
Adiponectin and AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells. BMC Cell Biol (2007) 1.10
Bone metabolism and fracture risk in type 2 diabetes mellitus [Review]. Endocr J (2011) 1.09
Plasma uric acid is associated with increased risk of type 2 diabetes independent of diet and metabolic risk factors. J Nutr (2012) 1.09
Hypophosphatemia and glucose intolerance: evidence for tissue insensitivity to insulin. N Engl J Med (1980) 1.08
Rapid normalization/stimulation by 1,25-dihydroxyvitamin D3 of insulin secretion and glucose tolerance in the vitamin D-deficient rat. Endocrinology (1987) 1.07
Tooth dentin defects reflect genetic disorders affecting bone mineralization. Bone (2012) 1.07
Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia. J Bone Miner Res (2013) 1.06
Serum leptin is associated with serum uric acid concentrations in humans. Metabolism (1999) 1.05
A patient with hypophosphatemic rickets and ossification of posterior longitudinal ligament caused by a novel homozygous mutation in ENPP1 gene. Bone (2011) 1.05
Uric acid best predicts metabolically unhealthy obesity with increased cardiovascular risk in youth and adults. Obesity (Silver Spring) (2013) 1.04
Dentin alteration of deciduous teeth in human hypophosphatemic rickets. Calcif Tissue Int (2006) 1.04
Leptin does not directly affect CNS serotonin neurons to influence appetite. Cell Metab (2011) 1.04
Clinical review: Genome-wide association studies of skeletal phenotypes: what we have learned and where we are headed. J Clin Endocrinol Metab (2012) 1.04
Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials. J Bone Miner Res (2013) 1.03
Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit Rev Eukaryot Gene Expr (2012) 1.03
Effects of hypophosphatemia on glucose tolerance and insulin secretion. Horm Metab Res (1998) 1.02
Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density. J Clin Endocrinol Metab (2004) 1.02
Leptin might be a regulator of serum uric acid concentrations in humans. Jpn Heart J (2003) 1.02
MEPE is a novel regulator of growth plate cartilage mineralization. Bone (2012) 1.01
FoxO1 protein cooperates with ATF4 protein in osteoblasts to control glucose homeostasis. J Biol Chem (2012) 1.01
MEPE's diverse effects on mineralization. Calcif Tissue Int (2009) 1.01
Leptin-dependent serotonin control of appetite: temporal specificity, transcriptional regulation, and therapeutic implications. J Exp Med (2010) 1.01
Metabolic consequences of ENPP1 overexpression in adipose tissue. Am J Physiol Endocrinol Metab (2011) 1.00
Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des (2013) 1.00
Regulation of renal gluconeogenesis by calcium ions, hormones and adenosine 3':5'-cyclic monophosphate. Biochem J (1973) 0.99
Hexa-D-arginine treatment increases 7B2•PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype. J Bone Miner Res (2013) 0.99
Serum uric acid levels in relation to bone-related phenotypes in men and women. J Clin Densitom (2012) 0.96
Mechanisms of disease: Ectonucleotide pyrophosphatase phosphodiesterase 1 as a 'gatekeeper' of insulin receptors. Nat Clin Pract Endocrinol Metab (2006) 0.96
LRP5, serotonin, and bone: complexity, contradictions, and conundrums. J Bone Miner Res (2011) 0.96
Leptin controls bone formation through a hypothalamic relay. Recent Prog Horm Res (2001) 0.95
Ioni control of renal gluconeogenesis. I. The interrelated effect of calcium and hydrogen ions. Biochim Biophys Acta (1973) 0.95
The renin-angiotensin system, blood pressure, and heart structure in patients with hereditary vitamin D-resistance rickets (HVDRR). J Bone Miner Res (2011) 0.95
Association of serum phosphate levels with glucose tolerance, insulin sensitivity and insulin secretion in non-diabetic subjects. Eur J Clin Nutr (2006) 0.95